
    
      This is a multicentre single arm clinical trial conducted in China,the purpose of this study
      is To Evaluate the Effectiveness and Safety of Anlotinib (12mg QD PO d1-14, 21 days per
      cycle)Combined with Docetaxel (75mg/m2 IV d1) for advanced Non-squamous non-small cell lung
      cancer.According to the result of TAX317,the PFS of second line standard chemotherapy was 3
      month. Expected the PFS was 5.7. Using PASS11, That calculated the sample size of this study
      was 41 , according to 10% censoring,the expected sample size is 46.
    
  